It's rare until it happens to You
  • Who We Are
  • //
  • Research
  • //
  • Partnering
  • //
  • Products
  • //
  • News
  • //
  • Awards
  • //
  • Links
  • //
  • Contact

August 21, 2019

Orphan Drug Company Names Envenomation Expert as New President of Rare Disease Therapeutics (PDF)

October 8, 2018

New Antivenom for Rattlesnake Bites Introduced by Rare Disease Therapeutics, Inc. (PDF)

April 30, 2014

FDA Approves New Liquid Form Of Treatment For Patients With Acute Lymphoblastic Leukemia (ALL) As Part Of A Combination Regimen (PDF)

September 13, 2011

Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation (PDF)

August 29, 2011

Mid-State Company Battles Rare Diseases (www.NewsChannel5.com)

August 5, 2011

Today Scorpions – Tomorrow Pit Vipers and Spiders (PDF)

August 3, 2011

Rare Disease Therapeutics, Inc. Obtains FDA Approval of Scorpion Sting Antivenom Anascorp® (PDF)

News

Rare Disease Therapeutics, Inc.

2550 Meridian Blvd, Suite 150
Franklin, Tennessee 37067
Phone: 615-399-0700
Fax: 615-399-1217

To report a suspected adverse reaction
or to order any of our products, please
call 844-472-7389.
RDT America's First
Exclusively Orphan
Drug Company
Partnering With Us
We continually seek to form strategic alliances to acquire orphan products. By partnering with Rare Disease Therapeutics, Inc., your organization can access our experience in many therapeutic, clinical, operational, and administrative areas. // GO
Research & Development
Our product research and development focuses on the areas of oncology, genetic disorders, hematology, metabolic and respiratory diseases, envenomations, opportunistic infections, and hepatic diseases. // GO
What are Orphan Drugs?
What are "Orphan Drugs"? Orphan products are drugs, biologics, or other therapeutics that treat diseases that affect fewer than 200,000 people in the United States. // GO
© Rare Disease Therapeutics, Inc. All Rights Reserved.
Privacy Statement & Terms of Use | Compliance | RDT-Web-010-E-ADM | May 2021
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Cookie Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT